CN104491041B - Gegen Qinlian oral fluid and preparation method thereof - Google Patents
Gegen Qinlian oral fluid and preparation method thereof Download PDFInfo
- Publication number
- CN104491041B CN104491041B CN201410827524.8A CN201410827524A CN104491041B CN 104491041 B CN104491041 B CN 104491041B CN 201410827524 A CN201410827524 A CN 201410827524A CN 104491041 B CN104491041 B CN 104491041B
- Authority
- CN
- China
- Prior art keywords
- weight
- add
- root
- preparation
- taken
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012530 fluid Substances 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 57
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 57
- 239000003814 drug Substances 0.000 claims abstract description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229940079593 drug Drugs 0.000 claims abstract description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000006228 supernatant Substances 0.000 claims abstract description 21
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 17
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 17
- 239000000706 filtrate Substances 0.000 claims abstract description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- 235000017443 Hedysarum boreale Nutrition 0.000 claims abstract description 14
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims abstract description 14
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 8
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 5
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims abstract description 5
- 238000011049 filling Methods 0.000 claims abstract description 5
- 235000012907 honey Nutrition 0.000 claims abstract description 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims abstract description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 claims abstract description 5
- 230000001954 sterilising effect Effects 0.000 claims abstract description 5
- 229940013618 stevioside Drugs 0.000 claims abstract description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019202 steviosides Nutrition 0.000 claims abstract description 5
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 4
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 4
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 4
- 238000005984 hydrogenation reaction Methods 0.000 claims description 12
- JKQOBWVOAYFWKG-UHFFFAOYSA-N molybdenum trioxide Chemical compound O=[Mo](=O)=O JKQOBWVOAYFWKG-UHFFFAOYSA-N 0.000 claims description 12
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 claims description 12
- 229910001948 sodium oxide Inorganic materials 0.000 claims description 12
- 235000014676 Phragmites communis Nutrition 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012669 liquid formulation Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- AZHSSKPUVBVXLK-UHFFFAOYSA-N ethane-1,1-diol Chemical compound CC(O)O AZHSSKPUVBVXLK-UHFFFAOYSA-N 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000001848 dysentery Diseases 0.000 abstract description 11
- 230000001142 anti-diarrhea Effects 0.000 abstract description 6
- 238000001556 precipitation Methods 0.000 abstract description 5
- 210000003205 muscle Anatomy 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 206010036067 polydipsia Diseases 0.000 abstract description 3
- 239000009636 Huang Qi Substances 0.000 abstract 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 abstract 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 abstract 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 abstract 1
- 229960003885 sodium benzoate Drugs 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 47
- 239000007788 liquid Substances 0.000 description 37
- 241001251949 Xanthium sibiricum Species 0.000 description 33
- 230000000694 effects Effects 0.000 description 22
- 238000010200 validation analysis Methods 0.000 description 17
- 230000037396 body weight Effects 0.000 description 16
- 210000002784 stomach Anatomy 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 12
- 239000012153 distilled water Substances 0.000 description 12
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 238000003304 gavage Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 8
- 229940012189 methyl orange Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000008838 gegenqinlian Substances 0.000 description 6
- 238000012449 Kunming mouse Methods 0.000 description 5
- 241000607764 Shigella dysenteriae Species 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- WITLAWYGGVAFLU-UHFFFAOYSA-N 3-(6-methoxy-1,3-benzodioxol-5-yl)-8,8-dimethylpyrano[2,3-f]chromen-4-one Chemical compound C1=CC(C)(C)OC2=CC=C(C(C(C3=CC=4OCOC=4C=C3OC)=CO3)=O)C3=C21 WITLAWYGGVAFLU-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229940007046 shigella dysenteriae Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- 206010057071 Rectal tenesmus Diseases 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000012271 tenesmus Diseases 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 241000282817 Bovidae Species 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010079058 casein hydrolysate Proteins 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 208000021735 chronic enteritis Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 208000013219 diaphoresis Diseases 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000001141 propulsive effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- XDQITMCFPPPMBC-TUANDBMESA-N scutelloside Natural products OC[C@H]1O[C@@H](O[C@@H]2O[C@@H]3C[C@H]4[C@H](O)[C@@H](O)[C@@](O)(CO3)[C@@H]24)[C@H](O)[C@@H](O)[C@@H]1O XDQITMCFPPPMBC-TUANDBMESA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000097 Abdominal tenderness Diseases 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 101100276976 Drosophila melanogaster Drak gene Proteins 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OSKIPPQETUTOMW-YHLOVPAPSA-N N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-Acetamido-5-[(2R,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3S,4S,5R,6R)-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxy-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 OSKIPPQETUTOMW-YHLOVPAPSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 241000607762 Shigella flexneri Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- IZPNTDOWOBGHEG-UHFFFAOYSA-M sodium benzene formate Chemical compound [Na+].[O-]C=O.C1=CC=CC=C1 IZPNTDOWOBGHEG-UHFFFAOYSA-M 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- XMVONEAAOPAGAO-UHFFFAOYSA-N sodium tungstate Chemical compound [Na+].[Na+].[O-][W]([O-])(=O)=O XMVONEAAOPAGAO-UHFFFAOYSA-N 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of Gegen Qinlian oral fluid, and it is prepared by each bulk drug of following parts by weight：40 60 parts of the root of kudzu vine, 15 25 parts of the Radix Astragali, 15 25 parts of the coptis, 10 20 parts of honey-fried licorice root.Preparation method is as follows：Secondary, collecting decoction is first added water to cook, is filtered；Filtrate is taken to be concentrated into the 1.25g/cm of density 1.103, gradient alcohol precipitation is carried out, alcohol content is respectively 30 55% and 60 85%；Take supernatant to add stevioside, sodium benzoate, ethylparaben, EDTA 2Na and the honey of amount of preparation, add appropriate amount of water, adjust pH to 2.0 5.0, stand；Take supernatant to add appropriate amount of water, adjust pH to 5.5 7.0, stand, take supernatant to add the sodium pyrosulfite of amount of preparation 0.05 0.15%, mix, filling, sterilizing, you can.The Gegen Qinlian oral fluid cures mainly expelling pathogenic factors from muscles for clearing heat, antidiarrheal stop dysentery；For dysentery, the hot polydipsia of body, lower profit is smelly dirty.
Description
Technical field
The present invention relates to oral preparation of Chinese traditional medicinal technical field, and in particular to a kind of Gegen Qinlian oral fluid, and the root of kudzu vine
A kind of reed mentioned in ancient books connects the preparation method of oral liquid.
Background technology
Gegen qinlian decoction is first recorded in Zhang Zhongjing《The Treatise on Fevrile Diseases》, it is made up of four taste Chinese medicines, the root of kudzu vine is monarch, and a kind of reed mentioned in ancient books, company, radix glycyrrhizae are
Assistant, its specially bright fleshy exterior of solution sun of anticipating, and in clearing stomach in heat, be the classic prescriptions of traditional Chinese medicine in this removing summer-heat and in inducing diaphoresis.The root of kudzu vine
A kind of reed mentioned in ancient books in flakes, Gegen Qinlian oral fluid be gegen qinlian decoction different dosage forms, also recorded in Chinese Pharmacopoeia.
Paper《The research of gegen qinlian decoction Compatibility Law》(the phase 512-518 of the Chinese herbal medicines such as Luo Jiabo .2005 the 4th) refers to
Go out：The root of kudzu vine and the coptis reduce the content of scutelloside, and the coptis reduces the content of glycyrrhizic acid, and the root of kudzu vine, radix scutellariae, radix glycyrrhizae make containing for jamaicin
Amount reduces, i.e., the root of kudzu vine, radix scutellariae, the coptis, the different compatibilities of the taste Chinese medicine of honey-fried licorice root four will influence scutelloside, sweet in Gegen Qinlian prescription
The content of the active ingredients such as oxalic acid, jamaicin, so as to influence drug effect.
Paper《Gegen qinlian decoction compatibility is studied with antipyretic medicine efficacy relation》(CHINA JOURNAL OF CHINESE MATERIA MEDICAs .2004 the 7th in remaining woods
Phase 663-666) point out：The root of kudzu vine can strengthen the effect of radix scutellariae, the coptis and honey-fried licorice root then antagonism, reduce △ T values, main function medicine
For radix scutellariae, the root of kudzu vine strengthens the effect of radix scutellariae, the effect of honey-fried licorice root and coptis antagonism radix scutellariae；In the antipyretic drug effect of gegen qinlian decoction
In, its best of breed is radix scutellariae, the root of kudzu vine, it is seen that for different drug effects, need to use different Gegen Qinlian formulas.
Paper《Influence of the gegen qinlian decoction difference compatibility to puerarin content》(wear the Chinese herbal medicines such as karat gold .2003 the 6th
Phase 506-509) point out：Containing caused by the coptis and the root of kudzu vine compatibility decocting liquid precipitation in may be relevant with the change of pH value containing Puerarin,
That is the change of even pH value is also possible to influence the content of active ingredient in Gegen Qinlian prescription, and this shows Gegen Qinlian preparation
Preparation method will also influence the content of active ingredient in final product.
The content of the invention
The technical problems to be solved by the invention are to provide a kind of Gegen Qinlian oral fluid, and the Gegen Qinlian oral fluid cures mainly
Expelling pathogenic factors from muscles for clearing heat, antidiarrheal stop dysentery；For dysentery, the hot polydipsia of body, lower profit is smelly dirty.
The technical solution adopted in the present invention is：
A kind of Gegen Qinlian oral fluid, the oral liquid are prepared by each bulk drug of following parts by weight：Root of kudzu vine 40-60
Part, radix scutellariae 15-25 parts, coptis 15-25 parts, honey-fried licorice root 10-20 parts.
The preparation method of above-mentioned Gegen Qinlian oral fluid is as follows：
(1) bulk drug (root of kudzu vine, radix scutellariae, the coptis and honey-fried licorice root) of formulation by weight is weighed, adds water to cook secondary, 1 is small every time
When, add 6-10 (quality) times water, second plus 5-8 (quality) times water, collecting decoction, filtering for the first time；
(2) it is 1.10-1.25g/cm to take filtrate to be concentrated into relative density3(80 DEG C), are cooled to room temperature, add ethanol to make containing alcohol
Amount reaches 30-55%, hydrogenation sodium oxide molybdena regulation pH to 7.5-9.0, stands 24 hours；
(3) supernatant is taken, adds ethanol to alcohol content to reach 60-85%, hydrogenation sodium oxide molybdena regulation pH to 7.5-9.0, stands
24 hours；
(4) supernatant is taken, reclaims ethanol, adds amount of preparation (mass percent) 0.03-0.06% stevioside, 0.03-
0.06% sodium benzoate, 0.03-0.06% ethylparabens, 0.1-0.2%EDTA-2Na and 3-6% honey, add water weight
To 0.5-1.5 times of bulk drug weight, boil, cool down, add salt acid for adjusting pH to stand 24-48 hours to 2.0-5.0；
(5) supernatant is taken, is filtered, is taken filtrate, add water weight to 0.5-1.5 times of bulk drug weight, hydrogenation sodium oxide molybdena is adjusted
PH to 5.5-7.0 is saved, is boiled, stands 24-48 hours；
(6) supernatant is taken, is filtered, is taken filtrate, add water weight to 0.5-1.5 times of bulk drug weight, adjusts pH to 5.5-
7.0, boil, add amount of preparation (mass percent) 0.05-0.15% sodium pyrosulfites, mix, filling, sterilizing, you can.
Gegen Qinlian oral fluid of the present invention be brown color to the supernatant liquid of sepia, be long placed in a small amount of precipitation；Mildly bitter flavor,
Sweet tea；Relative density is not less than 1.03, pH value 4.0-6.0.
Usage and dosage：Orally, each 10mL, 2 times a day.
The present invention is chosen the root of kudzu vine, radix scutellariae, the coptis and honey-fried licorice root and is carried out compatibility in specific proportions based on theory of traditional Chinese medical science,
Make the drug effect between each taste Chinese medicine complement each other in the allotment of amount, bring out the best in each other so that Gegen Qinlian oral fluid tool of the present invention
There is expelling pathogenic factors from muscles for clearing heat, antidiarrheal stop dysentery etc. to cure mainly function, for dysentery, the hot polydipsia of body, lower profit is smelly dirty.
In preparation method, the water extraction of (1) step, (2), (3) step gradient alcohol precipitation, for precipitating proteins, starch, colloid
Deng macromolecular substances, set pH is advantageous to the precipitation of invalid components, is stood under (4), (5) step acid condition finally to precipitate
Impurity, what is finally given produces liquid clear, and active constituent content is high, and impurity content is few.The sheet obtained by above step
Invention Gegen Qinlian oral fluid active constituent content is high, and major function is inducing diaphoresis heat-clearing, is not solved to treat diseases caused by external factors exterior syndrome, heat evil
In entering, the lower profit of body heat is shown as, excrement is smelly dirty, dysphoria with smothery sensation uncomfortable in chest, red tongue with yellowish fur, the illness of rapid pulse.Available for chordapsus, bacterium
Property the category root of kudzu vine Siberian cocklebur such as dysentery, diarrhea connect disorder.
The present invention uses oral liquid formulations form, and convenient to take, mouthfeel is fine, is easily received by patient, absorbs completely, rises
Effect is fast, and curative effect is high, and security is big during Clinical practice, suitable for promoting the use of for clinically relevant illness.
Embodiment
The present invention is further described in detail with reference to embodiments.It is noted that detailed description below is all to illustrate
Property, it is intended to provide further instruction to the present invention.Unless otherwise indicated, all scientific and technical terms that the present invention uses
With the identical meanings being generally understood that with the technical field of the invention personnel.
Embodiment 1：
The present embodiment Gegen Qinlian oral fluid is prepared by each bulk drug of following parts by weight：50 parts of the root of kudzu vine, radix scutellariae
18.75 parts, 18.75 parts of the coptis, 12.5 parts of honey-fried licorice root.It is prepared as follows to obtain：
(1) root of kudzu vine 500g, radix scutellariae 187.5g, coptis 187.5g, honey-fried licorice root 125g are weighed, adds water to cook secondary, 1 is small every time
When, add 8 times of quality water, second plus 6.5 times of quality water, collecting decoction, filtering for the first time；
(2) it is 1.10-1.25g/cm to take filtrate to be concentrated into relative density3Between (80 DEG C), be cooled to room temperature (can be from
So cooling, cooling circulating water can also be used to cool down), add ethanol alcohol content is reached 40%, hydrogenation sodium oxide molybdena adjust pH to
In the range of 7.5-9.0,24 hours are stood；
(3) supernatant is taken, adds ethanol to alcohol content to reach 70%, hydrogenation sodium oxide molybdena is adjusted in the range of pH to 7.5-9.0, quiet
Put 24 hours；
(4) supernatant is taken, adds amount of preparation (mass percent) 0.03-0.06% stevioside, 0.03-0.06% benzene
Sodium formate, 0.03-0.06% ethylparabens, 0.1-0.2%EDTA-2Na and 3-6% honey, add water to 1000mL, boil,
Cooling, salt acid for adjusting pH is added to stand 48 hours in the range of 2.0-5.0；
(5) supernatant is taken, is filtered, takes filtrate to add water to 1000mL, hydrogenation sodium oxide molybdena is adjusted in the range of pH to 5.5-7.0,
Boil, stand 48 hours；
(6) supernatant is taken, is filtered, takes filtrate to add water to 1000mL, is adjusted in the range of pH to 5.5-7.0, is boiled, add preparation
(mass percent) 0.05-0.15% sodium pyrosulfites are measured, are mixed, filling, sterilizing, you can.
Embodiment 2：
The present embodiment Gegen Qinlian oral fluid is prepared by each bulk drug of following parts by weight：60 parts of the root of kudzu vine, radix scutellariae
25 parts, 25 parts of the coptis, 20 parts of honey-fried licorice root.Root of kudzu vine 600g, radix scutellariae 250g, coptis 250g, honey-fried licorice root 200g are weighed, is configured to
1000mL Gegen Qinlian oral fluids, preparation method is the same as embodiment 1.
Embodiment 3：
The present embodiment Gegen Qinlian oral fluid is prepared by each bulk drug of following parts by weight：40 parts of the root of kudzu vine, radix scutellariae
15 parts, 15 parts of the coptis, 10 parts of honey-fried licorice root.Root of kudzu vine 400g, radix scutellariae 150g, coptis 150g, honey-fried licorice root 100g are weighed, is configured to
1000mL Gegen Qinlian oral fluids, preparation method is the same as embodiment 1.
Embodiment 4：The pharmacodynamic experiment of Gegen Qinlian oral fluid
Test medicine：
(1) Gegen Qinlian Tablets：Purchased from by Honghe Prefecture pharmaceutical factory；
(2) Gegen Qinlian oral fluid：Gained is prepared by the embodiment of the present invention 1.
Experimental animal：
Wistar big white mouse, Kun Ming mice, provided by laboratory animal room of Anhui Prov. Medical Science Inst..
(1) to the effect of big white mouse lactose diarrhoea
Take healthy Wistar male white rats, 160~180g of body weight.Be randomly divided into blank control group, Gegen Qinlian Tablets group,
Gegen Qinlian oral fluid is big, middle dose group.Every group of 8 big white mouse.Before experiment, each big white mouse body weight and stool grade are recorded.It is real
Each group is by corresponding group and dosage when testing, and 1 hour after gastric infusion, per mouse, gavage gives 50% lactose 1.5ml/100g bodies again
Weight, twice a day, continuous 5 days.And (big white mouse is put in metabolic cage, respectively for observation big white mouse changes of weight and stool grade daily
Record result).Stool grade：0 grade is normal stool；1 grade is the soft excrement of shaping；2 grades are non-forming soft excrement；3 grades are magma
Close excrement；4 grades are watery stools, the results list 1,2.
The change of body weight after the different oral lactose of group big white mouse of table 1
The change of excrement after the different oral lactose of group big white mouse of table 2
The * P compared with blank control group<0.05, * * P<0.01.
Table 1,2 results prove：Gegen Qinlian oral fluid and Gegen Qinlian Tablets have anti-diarrhea effect to Rat Experimental diarrhoea,
Compared with blank control group, there is notable difference.But the onset time of Gegen Qinlian oral fluid group is faster than Gegen Qinlian Tablets group.
(2) to the influence of small white mouse Intestinal propulsive rate
Take healthy Kun Ming mice, body weight 20~22g, ♀ ♂ half and half.It is random divide blank control group, Gegen Qinlian Tablets group,
Gegen Qinlian oral fluid heavy dose group, Gegen Qinlian oral fluid middle dose group.Every group 14.Test fasted for one day prior.Every group is pressed
1 hour after corresponding group and dosage gastric infusion, charcoal end, 10% Arabic gum suspension 0.2ml/20g bodies per mouse gavage to 5%
Weight.After 20 minutes animal is put to death with cervical dislocation.Cut open the belly immediately, alimentary canal is intactly extracted from orifice of the stomach to rectum end.
It is not added with drawing, is laid on glass plate, survey its total length, and record charcoal end forward position to the distance of orifice of the stomach, it is complete with intestines and stomach calculates it
Long percentage.The average value organized entirely is taken to be compared, statistical procedures, the results list 3.
Influence of the 3 different groups of table to small white mouse Intestinal propulsive rate
The * P compared with blank control group<0.05
As a result show：Gegen Qinlian oral fluid and Gegen Qinlian Tablets group, have and suppress mouse small intestine progradation, with blank
Control group relatively has significant difference.
(3) to the influence of Mouse Stomach emptying
Take healthy Kun Ming mice, 20~22g of body weight, male and female half and half.It is randomly divided into blank control group, Gegen Qinlian Tablets
Group, Gegen Qinlian oral fluid heavy dose group, Gegen Qinlian oral fluid middle dose group.Every group of 12 small white mouses.It is each to test the previous day
Group was by fasting after corresponding group and dosage gastric infusion 24 hours.After 4 hours before experiment are administered once again, filled to every small white mouse
The methyl orange aqueous solutions of stomach 0.2ml 0.1%.Put to death after 20 minutes, win stomach, be placed in beaker, add 10ml distilled water, it is big along stomach
Curved scissors whets the appetite, and gastric content is fully washed in distilled water, uses NaHCO3Adjust PH to 6~6.5.Separation takes supernatant, with day
This Shimadzu UV-240 type ultraviolet-visible photometers (wavelength 420um), 10ml distilled water is added to make with 0.1% methyl orange 0.2ml close
Radix is spent, compares methyl orange trap in every Mouse Stomach of each group, and the average Stomach residue rate of each group is calculated by following equation.
Statistical procedures.The results list 4.
Wherein：Methyl orange residual rate=(methyl orange trap/methyl orange trap radix in stomach) × 100 in stomach.
4 different groups of table are to influence (%) of the small white mouse to methyl orange gastric emptying
| Group | Mouse number (only) | Dosage (g/kg) | Methyl orange residual rate (X ± SD) in stomach |
| Blank control group | 12 | Distilled water | 34.72±7.58 |
| Gegen Qinlian Tablets group | 12 | 5.2 | 24.92±6.75** |
| Root of kudzu vine a kind of reed mentioned in ancient books oral liquid group | 12 | 5.2 | 17.96±4.01** |
| Root of kudzu vine a kind of reed mentioned in ancient books oral liquid group | 12 | 5.2 | 24.88±4.43** |
The * * P ＜ 0.01 compared with blank control group
The result of table 4 shows：Gegen Qinlian oral fluid, which has, promotes mouse gastric emptying, relatively has highly significant with control group
Sex differernce.
(4) In vitro Bactericidal Experiments
1. method：Dilution method sensitization test.
2. culture medium：1. broth bouillon；2. 0.5% blood-bouillon culture medium；3. caseinhydrolysate liquid culture medium.
3. inoculum prepares：
1. shigella dysenteriae, Escherichia coli, staphylococcus aureus, Pseudomonas aeruginosa：The strain of standard mattress is inoculated in into blood respectively to put down
Single bacterium colony is isolated after plate again, several colony inoculations of homomorphosis 35 DEG C of 12h in meat soup pipe is then taken, uses physiological saline
Bacterial concentration is corrected, makes its turbidity is identical with 0.5 Maxwell pipe (to use BaCl2System), content is about 1.5 × 108/ml。
2. streptococcus：Reference culture point is pure, take point pure bacterium colony kind 35 DEG C of mistakes in 0.5% blood-bouillon culture medium
At night, concentration is corrected with salt solution, turbidity is same as above.
4. test procedure：10, test tube is arranged, wherein the first pipe plus caseinhydrolysate fluid nutrient medium 1.9ml, remaining each pipe
Add 1ml, draw root of kudzu vine Siberian cocklebur and connect oral liquid and the root of kudzu vine Siberian cocklebur aqueous solution 0.1ml in flakes, add the mixing of the first pipe, suction out 1ml and add the
Two pipes, by that analogy to the 9th pipe, it is control tube that the tenth pipe, which is not added with decoction, takes the bacterium solution 0.5ml for having corrected concentration to add and respectively contains
Pencil and control tube, 35 DEG C overnight, observes result.
5. result：It is shown in Table 5 and table 6.
The root of kudzu vine Siberian cocklebur of table 5 connects the vitro antibacterial activity of oral liquid
| Drug concentration (mg/ml) | |
| The control strain control of 500mg 250mg 125mg 62.5mg 31.25mg 15.625mg medicines | |
| Shigella dysenteriae | ———————— |
| Escherichia coli | ———————— |
| Hemolytic streptococcus | ———————— |
| Staphylococcus aureus | ———————— |
| Pseudomonas aeruginosa | ———————— |
The vitro antibacterial activity of the root of kudzu vine Siberian cocklebur of table 6 aqueous solution in flakes
| Drug concentration (mg/ml) | |
| The control strain control of 500mg 250mg 125mg 62.5mg 31.25mg medicines | |
| Shigella dysenteriae | ——————— |
| Escherichia coli | ——————— |
| Hemolytic streptococcus | ——————— |
| Staphylococcus aureus | ——————— |
| Pseudomonas aeruginosa | ——————— |
"+" is to have bacteria growing, "-" asepsis growth.
Show from table 5,6 results：Gegen Qinlian oral fluid and Gegen Qinlian Tablets are to shigella dysenteriae, Escherichia coli, hemolytic
Streptococcus and staphylococcus aureus have different degrees of inhibitory action.MIC is respectively 31.25,31.25,125 and 250mg/
ml。
(5) Xylose Content is tested in mouse serum
Take healthy Kun Ming mice, 20 ± 2g of body weight, male and female half and half.It is randomly divided into blank control group, Gegen Qinlian Tablets
Group and two dosage groups of Gegen Qinlian oral fluid.Every group of 12 small white mouses.The previous day each group is tested to fill by corresponding group and dosage
Stomach administration is secondary.The experiment same day gavages again to be administered once.After one hour, each group gavages 5%D- xylose solution 2.1g/kg body weight,
After one hour, eye socket takes blood, prepares serum.And a mouse serum is taken, and add 8 parts of distilled water, 0.5 part of 0.3mol/1 sulfuric acid,
10% 0.5 part of sodium tungstate, with adding with shaking.Centrifugation removes protein, produces nonprotein filtrate, takes this filtrate 2ml, add
1% 2 antelope toluene reagent 2ml, mixes 1hr in rearmounted boiling water, and each pipe plus distilled water diluting mix to 25ml after cooling.Separately take 1
Branch blank tube adds distilled water 2ml, 2 each 2ml of xylose standard solution conduit (concentration is respectively 0.05mg/ml and 0.1mg/ml), its
Remaining method is same as above, and its trap is surveyed at 630nm wavelength, calculates Xylose Content in mouse serum.The results list 7.
Influence of the 7 different groups of table to Xiaobao mouse serum Xylose Content
The P compared with blank control group>0.05
Xylose is thermally formed bran aldehyde in an acidic solution, and it is in green reaction that the latter can be acted on two antelope toluene.Can from upper table
To find out：Root of kudzu vine Siberian cocklebur in flakes with oral liquid to small white mouse intestinal absorption without obvious facilitation.
(6) summarize
From pharmacodynamic results it can be seen that：Root of kudzu vine Siberian cocklebur connects oral liquid and had both remained the physiologically active of root of kudzu vine Siberian cocklebur in flakes, i.e., to breast
The anti-diarrhea effect of sugared rat diarrhoea, to the inhibitory action of mouse enterocinesia, promotes small white mouse emptying and In Vitro Bacteriostasis
Deng, and the agent in flakes of root of kudzu vine Siberian cocklebur is also substantially better than to mouse gastric emptying, the onset time of antidiarrheal is also faster than tablet control group.
Embodiment 5：The animal acute toxicity test of Gegen Qinlian oral fluid
Experimental animal：Kunming small white mouse, 20 ± 2g of body weight, male and female half and half, by animal housing of Anhui Prov. Medical Science Inst.
There is provided.
Experimental drug：Root of kudzu vine Siberian cocklebur connects oral liquid, and gained is prepared by the embodiment of the present invention 1.
(1) mouth medication：
Above-mentioned healthy Kun Ming mice 20 is taken, each gavage of every small white mouse connects oral liquid 0.8ml/ to root of kudzu vine Siberian cocklebur
20g body weight (contains crude drug 0.8g), 4 times in every 6 hours 1 time, 24 hours, after administration in Continuous Observation 7 days, and small white mouse toxic reaction
And death condition.As a result in seven days, freely, appetite and stool and urine are normal for small white mouse activity.Small white mouse toxic reaction is not found
And death condition.It is computed：Root of kudzu vine Siberian cocklebur connect oral liquid gastric infusion hair, measure mini bus maximal tolerance dose more than 320 grams of crude drugs/
Kg, equivalent to 960 times of clinically people's dosage.
(2) intraperitoneal injection method：
Take above-mentioned specification small white mouse, random pair is divided into 5 groups, every group 10, by 1:0.8 grade is administered than anxious number, every small
0.2ml/20g body weight is injected intraperitoneally in white mouse, Continuous Observation seven days after administration, records each group mice dying number, and carry out in time
Gross necropsy, lesion is not found, as a result see the table below 8.
Table 8
Use composite accounting：Try to achieve LD50=23.38g crude drugs/kg；LD5095% it is average it is credible be limited to 23.38 ±
1.98g/kg。
(3) summarize：
It is 320g crude drugs/kg that Gegen Qinlian oral fluid administration by gavage, which measures small white mouse maximal tolerance dose,；Intraperitoneal injection, which is surveyed, to be hindered
Small white mouse LD5O=23.38g crude drugs/kg.
Embodiment 6：The long-term toxicity test for animals of Gegen Qinlian oral fluid
Experimental animal：Wistar big white mouse, body weight 150 ± 10g, ♂ ♀ half and half, by Anhui Prov. Medical Science Inst. animal
Room provides.
Experimental drug：Embodiment 1 prepares gained root of kudzu vine Siberian cocklebur and connects oral liquid, every 10ml 10g containing crude drug, for ease of being administered,
It is condensed into every 2 grams of milliliter contained amount.
(1) experimental method：
Healthy Wistar big white mouse 60 are selected in experiment, and 150 ± 10g of body weight, male and female half and half, random pair is divided into blank pair
Connecting oral liquid heavy dose group according to group (daily gavage is to distilled water), root of kudzu vine Siberian cocklebur, (daily gavage connects oral liquid 40g/kg to root of kudzu vine Siberian cocklebur
120 times that dose is often used equivalent to Lin)；Root of kudzu vine Siberian cocklebur connects oral liquid small dose group, and (daily gavage connects oral liquid 9g/kg to root of kudzu vine Siberian cocklebur
Equivalent to 27 times of clinical application amount)；Successive administration one month, during administration, survey body weight per week once, is adjusted by body weight and used
Dose, and big white mouse activity, diet are observed daily and situations such as stool and urine, and record toxic reaction and dead animal number.Last
After administration, fasting 12 hours, after the first thought-read electrograph of each group big white mouse, then take a blood sample and survey blood routine, hepatic and renal function, and dissect naked eyes
Observe organ change, organ coefficient and main organs pathological examination.
(2) experimental result：
Above-mentioned big white mouse, activity, stool and urine and diet are normal during administration, body weight natural increase, have no obvious poison
Property reaction, normal ECG, dissection internal organ also no abnormality seen, blood routine, hepatic and renal function in normal range (NR), the results detailed in Table 9,
10、11、12、13、14。
The root of kudzu vine Siberian cocklebur of table 9 connects influence of the oral liquid to big white mouse body weight
The root of kudzu vine Siberian cocklebur of table 10 connects influence of the oral liquid to blood picture
| Group | Number of animals (only) | Dosage | Hb(g/L) | RBC×1012/L | RBC×109/L |
| Blank control group | 20 | Distilled water | 148.1±4.58 | 5.375±0.589 | 181.45±23.79 |
| Root of kudzu vine Siberian cocklebur connects oral liquid group | 20 | 40g/kg | 147±8.23 | 5.11±0.506 | 176±26.21 |
| Root of kudzu vine Siberian cocklebur connects oral liquid group | 20 | 9g/kg | 150±4.87 | 5.65±0.556 | 186.9±21.01 |
The root of kudzu vine Siberian cocklebur of table 11 connects influence of the oral liquid to blood picture
| Group | Number of animals (only) | Dosage | WBC(109/1) | L (%) | N (%) |
| Blank control group | 20 | Distilled water | 6.31±3.22 | 39.6±3.72 | 60.4±.78 |
| Root of kudzu vine Siberian cocklebur connects oral liquid group | 20 | 40g/kg | 6.38±2.81 | 41.7±3.51 | 58.3±3.53 |
| Root of kudzu vine Siberian cocklebur connects oral liquid group | 20 | 9g/kg | 6.9±2.31 | 39.6±3.5 | 60.4±3.33 |
The root of kudzu vine Siberian cocklebur of table 12 connects influence of the oral liquid to Rat Liver function
| Group | Number of animals (only) | Dosage | TP(g/l) | ALB(g/l) | SGPT(μ) | A/G |
| Blank control group | 20 | Distilled water | 62.63±2.5 | 31.81±3.19 | 28.75±5.81 | 1.1：1 |
| Root of kudzu vine Siberian cocklebur connects oral liquid group | 20 | 40g/kg | 61.67±2.39 | 31.56±2.13 | 28.22±4.29 | 1.05：1 |
| Root of kudzu vine Siberian cocklebur connects oral liquid group | 20 | 9g/kg | 61.11±3.18 | 31.44±2.51 | 28.89±8.13 | 1.08：1 |
The root of kudzu vine Siberian cocklebur of table 13 connects influence of the oral liquid to renal function
| Group | Mouse number (only) | Dosage | BUN(mmol/L) | Cr(μmol/L) |
| Blank control group | 20 | Distilled water | 4.3±0.416 | 74.09±6 |
| Root of kudzu vine Siberian cocklebur connects oral liquid group | 20 | 40g/kg | 4.1±0.57 | 70.44±11.56 |
| Root of kudzu vine Siberian cocklebur connects oral liquid group | 20 | 9g/kg | 4.52±0.447 | 75.44±7.28 |
The root of kudzu vine Siberian cocklebur of table 14 connects influence of the oral liquid to big white mouse organ coefficient
(3) summarize
Root of kudzu vine Siberian cocklebur connects oral liquid continuously to big white mouse gavage one month, dirty from blood routine, hepatic and renal function, electrocardiogram and whole body
The results such as device pathological examination see do not occur toxic reaction.So security is big when root of kudzu vine Siberian cocklebur connects oral liquid Clinical practice.
Embodiment 7：Gegen Qinlian oral fluid treats dysentery clinical verification
(1) study subject
Selection institute of traditional Chinese medicine of Anhui Province is in hospital and outpatient 63, meets《Pharmacopeia》Regulation Gegen Qinlian Tablets cure mainly model
To enclose, the dysentery of differential diagnosis in tcm category Gegen Qinlian card, doctor trained in Western medicine is diagnosed as bacillary dysentery person, and without severe malnutrition, severe
Dehydration, without other general diseases, while except with the diseases such as de-, coma, bleeding, twitch of fainting dysentery, during observation not
With in any antibiotic or other Chinese medicines, 63, male 33, women 30.The oldest person 63 years old, reckling 18 years old, put down
At equal 36.06 ± 11.68 years old age, the course of disease is most short 1 day, most long 20 days.63 patients, it is divided into two groups, control group 32, takes Pueraria lobota
Root a kind of reed mentioned in ancient books in flakes, validation group 31, takes Gegen Qinlian oral fluid, each group no difference of science of statistics (P in terms of sex, age, the course of disease
＞ 0.05).
(2) dialectical standard
1. dysentery diagnostic criteria
1. suffering from abdominal pain, being tenesmus, times of defecation, which increases, often has purulence blood is viscous to freeze；
2. being mainly in summer and autumn, having unhygienic diet history, acute attack can generate heat with malice；
3. positive rate of bacteria more than 80%.
2. the dialectical standard of Gegen Qinlian
1. defecating more than 3 times a day, increase (300 gram/day) with excrement amount and character changes (loose stools or watery stool, mucus
Just, pus and blood stool)；
2. body is warm, slight chill, or headache, body Chu；
3. excrement it is smelly it is dirty, tripe door is scorching hot, diarrhea is urgent, or rushes down and not well；
4. dysphoria with smothery sensation, thirsty, scanty drak urine；
5. tongue is red, yellow tongue fur, rapid pulse；
6. or and borborygmus, stomachache it is or tenesmus.
All possess 1,2 and 3, wantonly 1 or more than 1 person in 4,5, can be used as primary election identifying object, and the 6th is or simultaneous
Project.
(3) treatment method
Validation group takes the Gegen Qinlian oral fluid of the embodiment of the present invention 1,1 every time (10ml/ branch), twice a day.Control
Group takes Gegen Qinlian Tablets, and 5 tablets once, twice a day, purchased from Honghe state, Yunnan Province pharmaceutical factory.
(4) observation index
1. the effect of observation of curative effect, treatment group, control group, compares.
2. each primary symptom onset time, recover the observation of normal time.
3. stool culture positive rate and negative conversion rate, the observation of bacterial species, White blood cell.
(5) result
1st, efficacy result
The observation of curative effect of table 15
As can be seen from Table 15, checking curative effect is higher than control group, is statistically analyzed, and total effective rate compares without significantly between group
Sex differernce (p>0.05).
2nd, the observation of total white blood cells change
The observation (× 10 of the total white blood cells of table 16 change9/1)
| Group | n | Before treatment | After treatment |
| Control group | 32 | 9.55±4.07 | 6.76±2.66# |
| Validation group | 31 | 9.85±3.18 | 6.03±1.93# |
(#P<0.01)
As can be seen from Table 16, control group and validation group can significantly reduce total white blood cells (#P<0.01), but between group compare
Compared with there was no significant difference (#P>0.05)。
3rd, the observation of positive rate of bacteria and negative conversion rate
The observation of the positive rate of bacteria of table 17 and negative conversion rate
As can be seen from Table 17, the positive rate of bacteria of control group is slightly above validation group.After treatment, Bacteria Culture is turned out cloudy
Rate validation group is higher than control group.From control group with from the point of view of validation group bacteria cultivation results, mattress name be mostly Shigella shigae and
Shigella flexneri (accounts for 88.2%).
4th, each primary symptom onset time (h), the observation of recovery normal time (h) see the table below.
18 each primary symptom onset time (h) of table, the observation for recovering normal time (h)
(note：△P>0.05,#P>0.05)
Found out by table 18, validation group each primary symptom onset time and recovery normal time are smaller than control group.Times of defecation
Onset time, recover that statistically there was no significant difference normal time (△P ＞ 0.05,#P ＞ 0.05).
(6) summarize
1st, validation group and control group have the effect of identical and attending scope, and efficacy result is shown, Gegen Qinlian oral fluid
Curative effect is higher than Gegen Qinlian Tablets, but no difference of science of statistics (P ＞ 0.05).
2nd, validation group to improving, recovering clinical symptoms, the time of sign be smaller than control group, prompt validation group treating
Imitate the time and recover rapid compared with control group on normal time.
3rd, the Bacteria Culture negative conversion rate of validation group is higher than control group, may easily be absorbed with novel form, and bioavilability improves
It is relevant.
Generally speaking, the result shows, Gegen Qinlian oral fluid of the present invention has convenient to take, absorbs complete, works
The advantages of fast.
Embodiment 8：Gegen Qinlian oral fluid treats diarrhea clinical verification
(1) study subject
Selection institute of traditional Chinese medicine of Anhui Province is in hospital and outpatient 80, meets《Pharmacopeia》Regulation Gegen Qinlian Tablets cure mainly model
Enclose, Chinese medical discrimination belongs to damp and hot and hinders trencherman.Wherein man 8；Female 32；Age is minimum 18 years old, maximum 35 years old, average age
42.38 ± 13.28 years old.Disease includes chordapsus, chronic enteritis, chronic enteritis acute attack person.It is the course of disease most long January, most short
6 hours.Two groups are randomly divided into, control group 40, takes Gegen Qinlian Tablets；Validation group 40, take Gegen Qinlian mouth of the present invention
Take liquid, two groups of no difference of science of statistics (P in terms of sex, age, disease, the course of disease>0.05).
(2) treatment method
1st, validation group：Take the Gegen Qinlian oral fluid of the embodiment of the present invention 1, each 10ml (containing crude drug 10g), daily two
It is secondary；
2nd, control group：Gegen Qinlian Tablets (being purchased from Honghe Prefecture pharmaceutical factory) are taken, 5 tablets once (containing crude drug 10g), daily
2 times.
(3) observation index
1st, observe the symptoms and the pretherapy and post-treatment clinical change of sign, observation of curative effect and curative effect judge referring to《Clinical verification side
Case》.
2nd, each cardinal symptom, sign, laboratory checking index recover the observation of normal time.
3rd, medicine has no toxic side effect during observation treatment.
(4) result
1st, efficacy result, 19 are shown in Table.
19 two groups of efficacy analysis of table
Validation group and control group therapeutic effect, are statistically analyzed, two medicine total effective rate no significant differences, Gegen Qinlian mouth
It is consistent with Gegen Qinlian Tablets to take liquid curative effect, reaches《Pharmacopeia》Standard.
2nd, symptom, sign and laboratory examination recover normal time after treating：
20 two groups of recovery normal times (h) of table
| Validation group | Control group | |
| Heating | 74.70±49.89 | 84.0±46.98 |
| Stomachache | 101.09±43.17 | 103.71±47.13 |
| It is tenesmus | 75.43±40.23 | 82.29±53.41 |
| Abdominal tenderness | 98.40±45.17 | 103.30±41.82 |
Cardinal symptom and sign recover normal time, and validation group is slightly before control group.
(5) summarize
Gegen Qinlian oral fluid novel form has a good effect, works early, and mouthfeel is fair, it is convenient to take the advantages that, have preferably
Clinical value, it is proposed that popularization and application.
While above example 4-8 experiments are carried out using embodiment 1, the scheme of embodiment 2,3 is also carried out simultaneously
Parallel test, as a result approximate with the scheme works of embodiment 1, no longer burden description here.
The present embodiments relate to material, reagent and equipment, be to meet oral preparation of Chinese traditional medicinal unless otherwise instructed
The commercially available prod of technical field.
It is described above, only the preferred embodiments of the present invention, it is noted that for those skilled in the art
For, on the premise of the core technology of the present invention is not departed from, improvements and modifications can also be made, these improvements and modifications also should
Belong to the scope of patent protection of the present invention.Any change in the implication and scope suitable with claims of the present invention, all
It is considered as being included within the scope of the claims.
Claims (2)
- A kind of 1. application of Gegen Qinlian Chinese medicine compound prescription in oral liquid formulation is prepared, it is characterised in that：By following parts by weight Each bulk drug be prepared：Root of kudzu vine 40-60 parts, radix scutellariae 15-25 parts, coptis 15-25 parts, honey-fried licorice root 10-20 parts；The preparation method of the Gegen Qinlian oral fluid comprises the following steps,(1) weigh the bulk drug of formulation by weight, add water to cook it is secondary, 1 hour every time, for the first time plus 6-10 times of water, second plus 5-8 times of water, collecting decoction, filtering；(2) it is 1.10-1.25g/cm to take filtrate to be concentrated into relative density3, room temperature is cooled to, adds ethanol alcohol content is reached 30- 55%, hydrogenation sodium oxide molybdena regulation pH to 7.5-9.0, stand 24 hours；(3) supernatant is taken, adds ethanol to alcohol content to reach 60-85%, hydrogenation sodium oxide molybdena regulation pH to 7.5-9.0, it is small to stand 24 When；(4) take supernatant, reclaim ethanol, add amount of preparation 0.03-0.06% stevioside, 0.03-0.06% sodium benzoate, 0.03-0.06% ethylparabens, 0.1-0.2%EDTA-2Na and 3-6% honey, add water weight to the 0.5- of bulk drug weight 1.5 times, boil, cool down, add salt acid for adjusting pH to stand 24-48 hours to 2.0-5.0；(5) supernatant is taken, is filtered, is taken filtrate, add water weight to 0.5-1.5 times of bulk drug weight, hydrogenation sodium oxide molybdena regulation pH To 5.5-7.0, boil, stand 24-48 hours；(6) supernatant is taken, is filtered, is taken filtrate, add water weight to 0.5-1.5 times of bulk drug weight, adjusts pH to 5.5-7.0, Boil, add amount of preparation 0.05-0.15% sodium pyrosulfites, mix, filling, sterilizing, you can.
- 2. application of the Gegen Qinlian Chinese medicine compound prescription in oral liquid formulation is prepared described in claim 1, it is characterised in that：The root of kudzu vine The preparation method that a kind of reed mentioned in ancient books connects oral liquid formulation comprises the following steps,(1) weigh the bulk drug of formulation by weight, add water to cook it is secondary, 1 hour every time, for the first time plus 6-10 times of water, second plus 5-8 times of water, collecting decoction, filtering；(2) it is 1.10-1.25g/cm to take filtrate to be concentrated into relative density3, room temperature is cooled to, adds ethanol alcohol content is reached 30- 55%, hydrogenation sodium oxide molybdena regulation pH to 7.5-9.0, stand 24 hours；(3) supernatant is taken, adds ethanol to alcohol content to reach 60-85%, hydrogenation sodium oxide molybdena regulation pH to 7.5-9.0, it is small to stand 24 When；(4) take supernatant, reclaim ethanol, add amount of preparation 0.03-0.06% stevioside, 0.03-0.06% sodium benzoate, 0.03-0.06% ethylparabens, 0.1-0.2%EDTA-2Na and 3-6% honey, add water weight to the 0.5- of bulk drug weight 1.5 times, boil, cool down, add salt acid for adjusting pH to stand 24-48 hours to 2.0-5.0；(5) supernatant is taken, is filtered, is taken filtrate, add water weight to 0.5-1.5 times of bulk drug weight, hydrogenation sodium oxide molybdena regulation pH To 5.5-7.0, boil, stand 24-48 hours；(6) supernatant is taken, is filtered, is taken filtrate, add water weight to 0.5-1.5 times of bulk drug weight, adjusts pH to 5.5-7.0, Boil, add amount of preparation 0.05-0.15% sodium pyrosulfites, mix, filling, sterilizing, you can.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410827524.8A CN104491041B (en) | 2014-12-25 | 2014-12-25 | Gegen Qinlian oral fluid and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410827524.8A CN104491041B (en) | 2014-12-25 | 2014-12-25 | Gegen Qinlian oral fluid and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104491041A CN104491041A (en) | 2015-04-08 |
| CN104491041B true CN104491041B (en) | 2018-02-16 |
Family
ID=52932555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410827524.8A Active CN104491041B (en) | 2014-12-25 | 2014-12-25 | Gegen Qinlian oral fluid and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104491041B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105535146B (en) * | 2015-12-30 | 2020-01-24 | 广西壮族自治区花红药业股份有限公司 | Pretreatment method of radix puerariae, radix scutellariae and rhizoma coptidis composition medicinal materials |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1957997A (en) * | 2005-10-31 | 2007-05-09 | 天津市润拓生物技术有限公司 | Animal use compound medicament with effects of relieving the muscles and skin, clearing away heat, relieving darrhea, and relieving dysentery, and preparation method |
| CN101156907B (en) * | 2007-10-12 | 2010-05-19 | 南方医科大学 | A pueraria root scutellaria and coptis extract |
| CN101564387A (en) * | 2008-04-25 | 2009-10-28 | 天津医科大学 | Oral arginine ibuprofen liquid preparation |
| CN101455735A (en) * | 2008-11-25 | 2009-06-17 | 洛阳建辉牡丹应用技术研究中心 | Combination method of fever-reducing and thirst-quenching medicine |
| CN104940322A (en) * | 2015-07-25 | 2015-09-30 | 曹健 | Traditional Chinese medicine preparation for treating diarrhea |
-
2014
- 2014-12-25 CN CN201410827524.8A patent/CN104491041B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104491041A (en) | 2015-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108210866A (en) | Composition with invigorating the spleen to clear away damp pathogen effect and preparation method thereof | |
| CN102845749A (en) | Health-care composition capable of improving sleep and aiding in improving memory | |
| JP2022001572A (en) | Chinese medicine prescription flora capsule, manufacturing method thereof, and use of chinese medicine prescription flora capsule in manufacture of therapeutic agents for type 2 diabetes | |
| CN108992544A (en) | A kind of Chinese medicine composition for preventing and treating eye disease | |
| CN102895326B (en) | Traditional Chinese medicine composition for treating infantile common cold and preparation method for traditional Chinese medicine composition | |
| CN1813819B (en) | Hedgehog hydnum fruiting body or hyphostroma, culture extract, formulation and preparing method | |
| CN102578668B (en) | Beverage for assisting in reducing blood sugar | |
| CN101002929A (en) | Medicine for treating functional hypopepsia or complicating Helicobacter pylori infection, and its preparing method | |
| CN101856418A (en) | Pharmaceutical preparation for preventing nephritis and preparation method thereof | |
| CN104491041B (en) | Gegen Qinlian oral fluid and preparation method thereof | |
| CN106420955A (en) | Traditional Chinese medicine composition with blood glucose reduction assistance effect, preparation method and product of traditional Chinese medicine composition | |
| CN102813913A (en) | Sichuan blackberry extract composition | |
| CN103920140A (en) | Compound preparation for reducing blood glucose, body weight and fat for human | |
| CN101264203B (en) | Chinese and western medicine composition for treating diabetes | |
| CN109432287B (en) | Traditional Chinese medicine oral liquid for preventing and treating excessive heat syndrome of poultry qi system and preparation method thereof | |
| CN104367673B (en) | A kind of Chinese medicine composition treating Eimeria species | |
| CN102488825B (en) | Traditional Chinese medicine composition for treating beriberoid pyretic arthralgia and application of traditional Chinese medicine composition | |
| CN104687032A (en) | Health caring echinacea health product | |
| CN102920968A (en) | Application of traditional Chinese medicine composition to preparation of helicobacter pylori resisting medicine | |
| CN107854575A (en) | A kind of red green onion beverage with three high drop function and preparation method thereof | |
| CN104705634A (en) | Lucid ganoderma healthcare product for protecting health | |
| CN104740079A (en) | Phyllanthus emblica health-care traditional Chinese medicine composition | |
| CN111135223B (en) | Application of flavored herba Moslae oral liquid in preparation of medicine for treating infantile rotavirus enteritis complicated with myocardial injury | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN103301368A (en) | Medicament for treating hyperactivity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |